Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
No holdings reported for quarter Q3 2020 |
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
SPDR SER TR | 7 | Q2 2024 | 16.9% |
ATHIRA PHARMA INC | 7 | Q2 2024 | 4.9% |
ASTROTECH CORP | 7 | Q2 2024 | 2.8% |
FORTE BIOSCIENCES INC | 7 | Q2 2024 | 1.6% |
VERRICA PHARMACEUTICALS INC | 7 | Q2 2024 | 2.9% |
MILESTONE PHARMACEUTICALS IN | 7 | Q2 2024 | 1.0% |
LISATA THERAPEUTICS INC | 7 | Q2 2024 | 0.8% |
ISHARES TR | 6 | Q2 2024 | 25.0% |
ELIEM THERAPEUTICS INC | 6 | Q1 2024 | 6.4% |
ORAMED PHARMACEUTICALS INC | 6 | Q2 2024 | 2.7% |
View BML Capital Management, LLC's complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-08-07 |
N-PX | 2024-08-07 |
13F-HR/A | 2024-04-24 |
13F-HR | 2024-04-23 |
13F-HR/A | 2024-02-02 |
13F-HR | 2024-01-30 |
13F-HR | 2023-10-23 |
13F-HR | 2023-07-24 |
13F-HR | 2023-04-14 |
13F-HR | 2023-02-13 |
View BML Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.